Document is current
Any future updates will be listed below
-
Authors
Söreskog, E.
Lindberg, I.
Kanis, J.A.
Åkesson, K.E.
Willems, D.
Lorentzon, M.
Ström, O.
Berling, P.
Borgström, F.
-
Funding
Funding for this research was provided by:
UCB Pharma
Amgen
- License Information
-
More Information
Article History
Received: 27 August 2020
Accepted: 4 December 2020
First Online: 6 January 2021
Compliance with ethical standards
:
: ES, IL, and FB are employees of Quantify Research which was contracted and paid by UCB Pharma to conduct the study. The authors did not receive direct payment as a result of this work outside of their normal salary payments. PB and DW are employees of UCB Pharma. JAK reports grants from Amgen, Eli Lilly, and Radius Health; consulting fees from Theramex. JAK is the architect of FRAX® but has no financial interest. KEA reports lecture and advisory fees outside this work from Amgen, Astellas, Chugai, Renapharma, and UCB Pharma. ML received lecture fees outside this work from Amgen, Astellas, Eli Lilly, UCB Pharma, Radius Health, Meda, GE-Lunar, and Santax Medico/Hologic.
: Not applicable.
